UK approves monoclonal antibody treatment for COVID-19
The UK’s health regulator has approved an antibody treatment developed by Regeneron and Roche to prevent and treat COVID-19, it said on Friday, adding it was trying to roll it out to patients soon.
According to the Medicines and Healthcare Products Regulatory Agency (MHRA), the medicine Ronapreve may help avoid infection, relieve symptoms of severe COVID-19 infection, and reduce hospitalization.
“This treatment will be a significant addition to our armory to tackle COVID-19,” British health minister Sajid Javid said in a statement.
Ronapreve is available as an injection or an infusion. According to the MHRA, it binds tightly to the coronavirus at the lining of the respiratory system, preventing it from obtaining access to respiratory system cells.
Ronapreve belongs to a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the body to fight off infections. The drug is not intended to be used as a substitute for vaccination, the MHRA said.
Japan was the first country to approve Ronapreve for the treatment of mild to moderate COVID-19 infections last month.
FOLLOW US ON SOCIAL MEDIA AND SHARE WTX NEWS WITH YOUR FRIENDS AND FAMILY:
Facebook – Please like our page
Twitter – Twitter updates available in English and Arabic. Please follow us and we would love to hear from you
Instagram – Follow our pages in English and ArabicLeave a comment